EP1846037A4 - Methodes de traitement de diverses conditions par administration de l-arginine a liberation prolongee - Google Patents

Methodes de traitement de diverses conditions par administration de l-arginine a liberation prolongee

Info

Publication number
EP1846037A4
EP1846037A4 EP06733787A EP06733787A EP1846037A4 EP 1846037 A4 EP1846037 A4 EP 1846037A4 EP 06733787 A EP06733787 A EP 06733787A EP 06733787 A EP06733787 A EP 06733787A EP 1846037 A4 EP1846037 A4 EP 1846037A4
Authority
EP
European Patent Office
Prior art keywords
arginine
administration
methods
sustained release
various conditions
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP06733787A
Other languages
German (de)
English (en)
Other versions
EP1846037A1 (fr
Inventor
Eyal S Ron
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Palmetto Pharmaceuticals LLC
Original Assignee
Palmetto Pharmaceuticals LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US11/042,017 external-priority patent/US20050288372A1/en
Priority claimed from US11/107,395 external-priority patent/US20050288373A1/en
Application filed by Palmetto Pharmaceuticals LLC filed Critical Palmetto Pharmaceuticals LLC
Publication of EP1846037A1 publication Critical patent/EP1846037A1/fr
Publication of EP1846037A4 publication Critical patent/EP1846037A4/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L19/00—Products from fruits or vegetables; Preparation or treatment thereof
    • A23L19/01—Instant products; Powders; Flakes; Granules
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/17—Amino acids, peptides or proteins
    • A23L33/175—Amino acids
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/30—Dietetic or nutritional methods, e.g. for losing weight
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L7/00—Cereal-derived products; Malt products; Preparation or treatment thereof
    • A23L7/10—Cereal-derived products
    • A23L7/117—Flakes or other shapes of ready-to-eat type; Semi-finished or partly-finished products therefor
    • A23L7/126—Snacks or the like obtained by binding, shaping or compacting together cereal grains or cereal pieces, e.g. cereal bars
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A61K9/2081—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets with microcapsules or coated microparticles according to A61K9/50
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Food Science & Technology (AREA)
  • Nutrition Science (AREA)
  • Polymers & Plastics (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Mycology (AREA)
  • Pulmonology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Child & Adolescent Psychology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
EP06733787A 2005-01-24 2006-01-23 Methodes de traitement de diverses conditions par administration de l-arginine a liberation prolongee Withdrawn EP1846037A4 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US11/042,017 US20050288372A1 (en) 2003-09-29 2005-01-24 Methods of treating various conditions by administration of sustained released L-Arginine
US11/107,395 US20050288373A1 (en) 2002-10-24 2005-04-14 Methods of treating various conditions by administration of sustained release L-arginine
PCT/US2006/002127 WO2006081147A1 (fr) 2005-01-24 2006-01-23 Methodes de traitement de diverses conditions par administration de l-arginine a liberation prolongee

Publications (2)

Publication Number Publication Date
EP1846037A1 EP1846037A1 (fr) 2007-10-24
EP1846037A4 true EP1846037A4 (fr) 2008-03-12

Family

ID=56290773

Family Applications (1)

Application Number Title Priority Date Filing Date
EP06733787A Withdrawn EP1846037A4 (fr) 2005-01-24 2006-01-23 Methodes de traitement de diverses conditions par administration de l-arginine a liberation prolongee

Country Status (4)

Country Link
EP (1) EP1846037A4 (fr)
AU (1) AU2006208293A1 (fr)
CA (1) CA2595651A1 (fr)
WO (1) WO2006081147A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2809638C1 (ru) * 2023-05-24 2023-12-14 Федеральное государственное бюджетное учреждение науки Федеральный исследовательский центр питания, биотехнологии и безопасности пищи (ФГБУН "ФИЦ питания и биотехнологии") Продукт специализированный с аргинином

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101271538B1 (ko) 2011-06-24 2013-06-05 (주)이뮤노텍 유기산, l―카르니틴, l―아르기닌 및 니코틴아미드를 유효성분으로 포함하는 비만의 예방 및 개선용 조성물
IL330086A (en) * 2023-12-26 2026-08-01 Rambam Med Tech Ltd The compounds and their use for the treatment of metabolic syndrome

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0441119A2 (fr) * 1990-01-09 1991-08-14 Richard D. Levere Utilisation du L-arginine pour le traitement de l'hypertension et d'autres troubles vasculaires
WO2000045651A1 (fr) * 1999-02-02 2000-08-10 Novartis Nutrition Ag Ingestion d'arginine et secretion d'insuline
US6475530B1 (en) * 2000-05-31 2002-11-05 Eric H. Kuhrts Methods and compositions for producing weight loss
US20030078269A1 (en) * 2001-03-22 2003-04-24 Chronorx, Llc Biguanide and sulfonylurea formulations for the prevention and treatment of insulin resistance and type 2 diabetes mellitus
WO2004037203A2 (fr) * 2002-10-24 2004-05-06 Enos Pharmaceuticals, Inc. Preparations de l-arginine a liberation prolongee et procedes de fabrication et d'utilisation de celles-ci
US20040180077A1 (en) * 2003-03-05 2004-09-16 Riker Donald K. Rapidly dissolving edible strips for treating obesity

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4920098A (en) * 1986-09-17 1990-04-24 Baxter International Inc. Nutritional support or therapy for individuals at risk or under treatment for atherosclerotic vascular, cardiovascular, and/or thrombotic diseases
SE9600070D0 (sv) * 1996-01-08 1996-01-08 Astra Ab New oral pharmaceutical dosage forms
US6174548B1 (en) * 1998-08-28 2001-01-16 Andrx Pharmaceuticals, Inc. Omeprazole formulation
SK16982002A3 (sk) * 2000-06-09 2003-04-01 Lek Pharmaceuticals D. D. Stabilizovaná farmaceuticky účinná kompozícia a liečivý prípravok túto kompozíciu obsahujúci

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0441119A2 (fr) * 1990-01-09 1991-08-14 Richard D. Levere Utilisation du L-arginine pour le traitement de l'hypertension et d'autres troubles vasculaires
WO2000045651A1 (fr) * 1999-02-02 2000-08-10 Novartis Nutrition Ag Ingestion d'arginine et secretion d'insuline
US6475530B1 (en) * 2000-05-31 2002-11-05 Eric H. Kuhrts Methods and compositions for producing weight loss
US20030078269A1 (en) * 2001-03-22 2003-04-24 Chronorx, Llc Biguanide and sulfonylurea formulations for the prevention and treatment of insulin resistance and type 2 diabetes mellitus
WO2004037203A2 (fr) * 2002-10-24 2004-05-06 Enos Pharmaceuticals, Inc. Preparations de l-arginine a liberation prolongee et procedes de fabrication et d'utilisation de celles-ci
US20040180077A1 (en) * 2003-03-05 2004-09-16 Riker Donald K. Rapidly dissolving edible strips for treating obesity

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of WO2006081147A1 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2809638C1 (ru) * 2023-05-24 2023-12-14 Федеральное государственное бюджетное учреждение науки Федеральный исследовательский центр питания, биотехнологии и безопасности пищи (ФГБУН "ФИЦ питания и биотехнологии") Продукт специализированный с аргинином

Also Published As

Publication number Publication date
WO2006081147A1 (fr) 2006-08-03
AU2006208293A1 (en) 2006-08-03
CA2595651A1 (fr) 2006-08-03
EP1846037A1 (fr) 2007-10-24

Similar Documents

Publication Publication Date Title
IL216401A0 (en) Sustained release of antinfectives
IL186616A0 (en) Spiro-oxindole compounds and their uses as therapeutic agents
IL186615A0 (en) Spiroheterocylic compounds and their uses as therapeutic agents
ZA200808178B (en) Imidazolothiazole compounds for the treatment of disease
GB0609492D0 (en) Therapeutic agents
IL192880A0 (en) Therapeutic uses of inhibitors of rtp801
GB0601962D0 (en) Therapeutic agents
SI2137141T1 (sl) Arilamidi bifenil-4-il-sulfonske kisline in njihova uporaba kot terapevtska sredstva
ZA200806074B (en) Compounds for the treatment of inflammatory disorders
PL2225238T3 (pl) Pochodne amidów kwasu 6,7-dihydro-5H-imidazo[1,2-a]imidazolo-3-karboksylowego
LT2229369T (lt) 6,7-dialkoksi-chinazolino dariniai, tinkami panaudoti su vėžiu susijusių susirgimų gydymui
GB0616214D0 (en) Therapeutic Agents
EP1968603A4 (fr) Composes therapeutiques amine-arylsulfonamide conjugues
PL2102174T3 (pl) Sposób wytwarzania pochodnych podstawionych cyjanofenoksy-pirymidynyloksyfenyloakrylanów
EP2250415A4 (fr) Collier d'ancrage
EP2157089A4 (fr) Utilisations thérapeutiques de dérivés d'acide imidazol-5-carboxylique
GB0620059D0 (en) Therapeutic agents
GB0609676D0 (en) Therapeutic agents
ZA200805701B (en) Salts of styphnic acid
GB0501129D0 (en) Method of treatment by administration of RNA
ZA200708853B (en) Methods of treatment utilizing certain melatonin derivatives
GB0618309D0 (en) Compositions and methods for the treatment of disease
GB0623740D0 (en) Treatment of disease
EP2056811A4 (fr) Traitement à base de modafinil contre l'éjaculation précoce
GB0622195D0 (en) Therapeutic agents

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20070824

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI SK TR

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: PALMETTO PHARMACEUTICALS, LLC

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 9/22 20060101ALI20080131BHEP

Ipc: A61P 3/06 20060101ALI20080131BHEP

Ipc: A61P 3/10 20060101ALI20080131BHEP

Ipc: A61P 11/06 20060101ALI20080131BHEP

Ipc: A61P 3/04 20060101ALI20080131BHEP

Ipc: A61K 31/198 20060101ALI20080131BHEP

Ipc: A61K 9/52 20060101ALI20080131BHEP

Ipc: A61K 47/32 20060101AFI20060809BHEP

A4 Supplementary search report drawn up and despatched

Effective date: 20080207

DAX Request for extension of the european patent (deleted)
17Q First examination report despatched

Effective date: 20080724

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20081204